TABLE 1.
Baseline demographic and disease characteristics by JESREC subgroup
| Non‐ECRS (n = 73) | Mild ECRS (n = 61) | Moderate ECRS (n = 144) | Severe ECRS (n = 160) | p value (non‐/mild versus moderate/severe ECRS) a | |
|---|---|---|---|---|---|
| Age, years | 53.10 (12.87) | 54.07 (11.28) | 51.39 (12.21) | 51.46 (12.93) | 0.1022 |
| Male sex, n (%) | 50 (68.5) | 48 (78.7) | 91 (63.2) | 82 (51.3) | 0.0013 |
| Weight, kg | 79.64 (14.74) | 84.98 (17.68) | 81.06 (18.74) | 76.82 (18.39) | 0.0824 |
| Bilateral endoscopic NPS, b range 0–8 | 5.88 (1.25) | 5.98 (1.21) | 6.27 (1.16) c | 6.14 (1.25) d | 0.0266 |
| Daily NC score, b range 0–3 | 2.46 (0.61) | 2.35 (0.62) | 2.41 (0.60) | 2.47 (0.56) | 0.5932 |
| LMK‐CT score, b range 0–24 | 16.44 (4.33) | 15.87 (3.49) | 18.33 (3.33) | 19.11 (3.40) | <0.0001 |
| TSS, b range 0–9 | 7.21 (1.52) | 6.88 (1.50) | 7.13 (1.53) | 7.45 (1.31) | 0.1220 |
| LoSS, b range 0–3 | 2.71 (0.57) | 2.52 (0.63) | 2.75 (0.59) | 2.85 (0.36) | 0.0009 |
| Smell test (UPSIT) score, b range 0–40 | 15.14 (8.96) e | 17.37 (8.90) f | 13.33 (7.78) g | 11.60 (6.53) h | <0.0001 |
| SNOT‐22 total score, b range 0–110 | 47.14 (19.23) | 49.20 (22.10) | 54.06 (21.60) c | 53.05 (20.39) i | 0.0120 |
| CRSwNP severity (VAS) score, b range 0–10 cm | 7.65 (2.23) j | 7.64 (2.18) | 8.22 (2.07) k | 8.12 (1.98) h | 0.0175 |
| Patients with comorbid asthma, n (%) | 28 (38.4) | 0 | 81 (56.3) | 153 (95.6) | <0.0001 |
| Patients with comorbid NSAID‐ERD, n (%) | 14 (19.2) | 0 | 43 (29.9) | 60 (37.5) | <0.0001 |
| Blood eosinophils, Giga/L | 0.13 (0.09) | 0.24 (0.15) | 0.41 (0.31) | 0.67 (0.37) | <0.0001 |
|
Eosinophils ≥150 cells/μl, n (%) |
19 (26.0) | 55 (90.2) | 137 (95.1) | 160 (100) | <0.0001 |
|
Eosinophils ≥300 cells/μl, n (%) |
7 (9.6) | 9 (14.8) | 87 (60.4) | 152 (95.0) | <0.0001 |
|
Eosinophils ≤2%, n (%) |
55 (75.3) | 0 | 0 | 0 | |
|
Eosinophils >2%–≤ 5%, n (%) |
18 (24.7) | 59 (96.7) | 76 (52.8) | 4 (2.5) | |
|
Eosinophils >5%–≤10%, n (%) |
0 | 1 (1.6) | 54 (37.5) | 100 (62.5) | |
|
Eosinophils >10%, n (%) |
0 | 1 (1.6) | 14 (9.7) | 56 (35.0) | <0.0001 |
| Periostin, ng/ml | 91.27 (37.76) | 90.26 (30.71) l | 113.52 (46.89) c | 123.26 (53.47) d | <0.0001 |
| Total IgE, IU/ml | 198.89 (251.85) | 185.38 (268.77) l | 266.83 (428.23) c | 260.09 (319.26) | 0.0489 |
Data are presented as mean (SD) unless otherwise stated.
Abbreviations: CRSwNP, chronic rhinosinusitis with nasal polyps; ECRS, eosinophilic chronic rhinosinusitis; IgE, immunoglobulin E; JESREC, Japanese Epidemiological Survey of Refractory Eosinophilic Rhinosinusitis; LMK‐CT, Lund‐Mackay score assessed by CT scan; LoSS, loss of sense of smell; NC, nasal congestion; NPS, nasal polyp score; NSAID‐ERD, nonsteroidal antiinflammatory drug‐exacerbated respiratory disease; SD, standard deviation; SNOT‐22, 22‐item Sinonasal Outcome Test; TSS, Total Symptom Score; UPSIT, University of Pennsylvania Smell Identification Test; VAS, visual analog scale.
p values were obtained using a t‐test for equality of variance. In cases where the equality of variance assumption was not met, Satterthwaite's p value was calculated. p values were obtained using the chi‐square test. In cases with an expected cell frequency <5, Fisher's exact test was used.
Higher scores indicate greater disease severity, except for UPSIT, where higher scores indicate lower disease severity.
n = 143.
n = 159.
n = 71.
n = 59.
n = 141.
n = 156.
n = 157.
n = 72.
n = 140.
n = 60.